Every Form 4 that DENTSPLY SIRONA Inc. (XRAY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XRAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRAY filings page.
DENTSPLY SIRONA Inc. senior executive Robert Anthony Johnson, SVP and Chief Supply Chain Officer, reported routine equity compensation grants. On January 9, 2026, he acquired 641.625 shares of common stock at a price of $0, representing dividends on existing restricted stock units paid in the form of additional RSUs that vest on the same schedule as the underlying awards. After this, he beneficially owned 116,313.146 shares of common stock directly.
On the same date, he was credited with 40.22 phantom stock units under the Supplemental Executive Retirement Plan at a reference price of $12.22 per unit, bringing his total phantom stock balance to 3,113.1526 units. Each RSU and each phantom stock unit is economically equivalent to one share of common stock, with phantom stock payable in common stock upon his termination of employment.
DENTSPLY SIRONA Inc. director Clyde Hosein reported an automatic stock acquisition tied to his existing equity awards. On 01/09/2026, he received 355.0455 shares of common stock at a price of $0, described as dividends on restricted stock units (RSUs) that are paid in the form of additional RSUs.
The footnote explains that these dividend RSUs carry the same vesting terms as the original RSU awards and will vest at the same time as the underlying grants, with each RSU converting into one share of common stock. Following this transaction, Hosein directly beneficially owned 41,252.522 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Betsy D. Holden reported an automatic share acquisition tied to her existing equity awards. On January 9, 2026, she acquired 710.956 shares of common stock at a price of $0, reflecting dividends on her restricted stock units (RSUs) that were paid in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying awards, and each RSU converts into one share of common stock. Following this transaction, Holden beneficially owned 54,613.852 shares of DENTSPLY SIRONA common stock in direct ownership.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported receiving additional equity-linked compensation. On 01/09/2026, he acquired 314.959 shares of common stock at a price of $0, reported as directly owned. After this transaction, he beneficially owned 29,041.522 shares of DENTSPLY SIRONA common stock.
According to the footnote, these shares represent dividends on existing restricted stock units (RSUs), credited in the form of additional RSUs. These dividend RSUs carry the same vesting terms as the underlying RSU awards, vest simultaneously with them, and each RSU converts into one share of common stock.
DENTSPLY SIRONA Inc. reported that senior vice president and chief human resources officer Andrea L. Frohning acquired additional equity-linked awards on January 9, 2026. She received 392.387 shares of common stock at a price of $0, described as dividends on restricted stock units that are credited as additional RSUs and vest on the same schedule as the underlying awards. After this, she beneficially owned 34,002.252 shares of common stock directly.
Frohning also acquired 22.7283 shares of phantom stock at $12.22 per unit under a Supplemental Executive Retirement Plan, bringing her total phantom stock holdings to 1,759.2738 units. Each phantom stock unit and each RSU is economically equivalent to one share of common stock, with phantom stock payable in common stock upon her termination of employment and RSUs converting into common stock on a 1:1 basis at vesting.
DENTSPLY SIRONA Inc. director Willie A. Deese reported an automatic stock-related transaction. On 01/09/2026, he acquired 201.508 shares of common stock at a price of $0. These shares represent dividends on previously granted restricted stock units (RSUs), paid in the form of additional RSUs that carry the same vesting schedule as the original awards.
Following this transaction, Deese directly beneficially owned 57,748.066 shares of DENTSPLY SIRONA common stock. Each RSU converts into one share of common stock on a 1:1 basis, and the dividend RSUs vest at the same time as the underlying RSUs they relate to.
DENTSPLY SIRONA Inc. VP and Chief Accounting Officer Kevin Czerney reported routine equity-related awards. On January 9, 2026, he acquired 262.7169 shares of common stock at $0, representing dividends paid in the form of additional restricted stock units that follow the same vesting schedule as the underlying RSUs, each converting into one share of common stock.
On the same date, he also acquired 4.0523 shares of phantom stock under the Dentsply Supplemental Savings Plan and 45.13 shares of phantom stock under the Supplemental Executive Retirement Plan at an economic value of $12.22 per phantom share, each economically equivalent to one share of common stock and payable in stock upon termination of employment. Following these transactions, his reported holdings increased to 28,040.786 shares of common stock, 341.201 phantom shares in the savings plan, and 3,493.4336 phantom shares in the retirement plan.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an automatic stock-related transaction. On 01/09/2026, he acquired 245.816 shares of common stock at a price of $0, bringing his directly held beneficial ownership to 17,944.987 shares.
The new shares come from dividends on restricted stock units (RSUs). These dividends were credited in the form of additional RSUs that follow the same vesting schedule as the original RSU awards. Each RSU converts into one share of common stock when it vests, so the reported amount reflects stock tied to his existing equity compensation rather than an open-market purchase.
DENTSPLY SIRONA Inc. director reports open-market stock purchase
A director of DENTSPLY SIRONA Inc. (XRAY) reported buying common stock in the company. On 11/24/2025, the reporting person purchased 9,337 shares of common stock at a price of $10.71 per share, in an open-market transaction coded as a purchase. After this transaction, the director beneficially owns 57,342.925 shares of DENTSPLY SIRONA common stock, held directly. This filing is a routine Form 4 disclosure of insider trading activity required under U.S. securities regulations.
DENTSPLY SIRONA (XRAY) disclosed a Form 4 for an officer, SVP and Chief Supply Chain Office, reporting two stock option grants on 11/07/2025. The filings show awards of 417,200 options at an exercise price of $11.18 and 361,700 options at $12.3, each recorded as an acquisition (Code A) with $0 option price, indicating grants. Both grants are held directly and will cliff-vest on the third anniversary of the grant date (11/07/2028), with expiration on 11/07/2035. The second grant’s exercise price equals 110% of the issuer’s closing price on the grant date.
DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.
The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.
DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On 10/10/2025, the SVP, Chief Supply Chain Office reported 972.381 shares of common stock acquired at $0, credited as dividends on restricted stock units that vest with the underlying awards and convert 1:1 into common stock.
The filing also reports 40.5116 phantom stock units under the SERP acquired at $11.98, each economically equivalent to one share and payable in stock upon termination of employment. Following these entries, direct ownership stands at 124,187.521 common shares and 3,072.9326 phantom stock units.
DENTSPLY SIRONA (XRAY) reported a routine insider update: Director Janet S. Vergis acquired 179.449 additional common shares on 10/10/2025, recorded at $0, from dividend equivalents on previously granted restricted stock units (RSUs). The acquisition is coded “A.”
Following the transaction, her beneficial ownership stands at 44,300.167 common shares, held directly. The filing notes these credits reflect RSU dividend equivalents that vest on the same schedule as the related RSUs, with each RSU converting to one share.
DENTSPLY SIRONA (XRAY) director reported an equity accrual. On 10/10/2025, the reporting person acquired 179.449 units at $0, reflecting dividends credited on previously awarded RSUs that carry the same vesting terms. Each RSU converts to common stock on a 1:1 basis.
Following this transaction, beneficial ownership stood at 48,005.925 on a direct basis. These credits represent routine dividend equivalents tied to outstanding RSUs rather than open‑market purchases.
DENTSPLY SIRONA (XRAY) reported insider equity accruals. Officer Richard C. Rosenzweig received 766.323 shares of common stock on 10/10/2025 at $0 (code A) from dividends on previously awarded RSUs that vest with the underlying awards. Following the transaction, directly held common stock was 85,183.54 shares.
He also acquired 80.9848 shares of phantom stock under the Supplemental Executive Retirement Plan at a derivative price of $11.98, bringing directly held phantom units to 6,142.9981. Each RSU and phantom unit is equivalent to one share of common stock, with phantom stock payable upon termination of employment.
DENTSPLY SIRONA (XRAY) director reported routine equity accruals. On 10/10/2025, the reporting person acquired 359.576 shares of common stock at $0 as dividend equivalents on previously granted RSUs. Following this transaction, directly held common stock totaled 28,451.376 shares.
The filing also shows an acquisition of 123.3618 units of phantom stock under the Directors' Deferred Compensation plan at a derivative price of $11.98. Phantom stock represents the economic equivalent of common stock and becomes payable in shares upon the director’s termination of service. After this accrual, the director held 11,743.5642 phantom stock units.
Notes clarify these were dividend-related accruals for RSUs and phantom stock, with RSUs converting to common stock on a 1:1 basis and phantom stock payable in common stock upon termination.
DENTSPLY SIRONA (XRAY): Form 4 insider transaction by a director. On 10/10/2025, 310.397 shares of common stock were acquired at $0 as dividends on restricted stock units credited to a Family Partnership. Following this, beneficial holdings were 24,357.397 shares indirect by Family Partnership, 82,301.434 shares direct, and 21,000 shares indirect by a Gregory Lucier IRA.
On 10/14/2025, the reporting person made a gift (Code G) of 17,200 non‑qualified stock options with a $12.96 exercise price to a Family Partnership. These options are exercisable beginning 08/08/2026 and expire on 08/08/2035. The filing notes the gift and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.
DENTSPLY SIRONA (XRAY) reported an insider equity change by director Betsy D. Holden. On 10/10/2025, the filing lists Common Stock acquired under code “A” totaling 646.937 at $0. The footnote explains these reflect dividend equivalents on restricted stock units (RSUs) credited as additional RSUs, which vest on the same schedule as the underlying awards, and each RSU converts to common stock on a 1:1 basis. Following the transaction, Holden beneficially owned 53,902.896 shares, held directly.
DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by SVP, CHRO Andrea Frohning. On 10/10/2025, she acquired 357.053 shares of common stock at $0, representing dividend equivalents on previously awarded RSUs that vest with their underlying awards; each RSU converts to common stock on a 1:1 basis.
She also acquired 22.893 shares of phantom stock under the Supplemental Executive Retirement Plan at a $11.98 derivative security price; phantom stock is economically equivalent to common stock and becomes payable in common stock upon termination of employment. Following these transactions, she beneficially owned 33,609.865 shares of common stock directly and 1,736.5455 phantom stock units directly.
DENTSPLY SIRONA (XRAY) filed a Form 4 for director Willie A. Deese. On 10/10/2025, 179.449 restricted stock units were acquired at $0 under code A as dividend equivalents on existing RSUs. After this entry, beneficial ownership is 57,546.558 shares, held directly. These dividend RSUs follow the same vesting schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
DENTSPLY SIRONA (XRAY) executive Kevin Czerney, VP and Chief Accounting Officer, reported routine equity accruals. On 10/10/2025, he acquired 233.911 RSUs as dividend equivalents at $0, which vest on the same schedule as the underlying RSUs.
Following these transactions, his direct beneficial ownership of common stock is 27,264.0691 shares. The filing notes this includes 112.5060 shares acquired through dividend reinvestment on 10/10/2025.
He was also credited 45.4596 phantom stock units under the SERP and 4.4453 phantom stock units under the DSSP at $11.98 per unit, each economically equivalent to one common share and payable in common stock upon termination of employment.
DENTSPLY SIRONA (XRAY) director reported an equity change tied to restricted stock units. On 10/10/2025, the reporting person acquired 223.681 RSU dividend equivalents at $0. According to the footnote, these represent dividends on RSUs credited as additional RSUs, vesting on the same schedule as the underlying awards, with each RSU converting to common stock on a 1:1 basis.
Following this transaction, the reporting person beneficially owned 17,699.171 shares, held directly.